Italian firm Technogenetics will be marketing the test – which uses Axis-Shield's technology to monitor antibodies to provide early warning of the condition – in Europe.
Chief executive Ian Gilham described it as an "important milestone" in the commercial development of the technology. Shares in the company rose by 0.5p to 269.5p.